Clinical Trial Update: A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating itacitinib for prevention of cytokine release syndrome in patients undergoing immune effector cell therapy has completed with results p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cytokine Release Syndrome

Drugs mentioned

• Itacitinib (itacitinib)

Snippet

Sponsor: Incyte Corporation | Conditions: Cytokine Release Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2024-03-26